文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗成人中重度特应性皮炎:5年开放标签扩展研究

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.
PubMed 文献 · JAMA Dermatol · 2024-01-01

该5年开放标签扩展研究纳入2677例成人中重度特应性皮炎患者,评估度普利尤单抗长期安全性与疗效。最常见不良事件包括鼻咽炎、AD加重、上呼吸道感染、结膜炎等;第260周时67.5%患者达到IGA 0/1,88.9%达到EASI 75%改善。结论为持续长期治疗安全有效。

要点

  • 度普利尤单抗治疗成人中重度AD长达5年,安全性总体稳定。
  • 第260周67.5%患者IGA 0/1,88.9%达EASI 75%改善。
  • 常见不良事件包括鼻咽炎、AD加重、上呼吸道感染、结膜炎等。

核心结论

  • 成人中重度AD连续长期使用度普利尤单抗5年,安全性和疗效持续。

研究设计与样本

  • 5年LIBERTY AD开放标签扩展研究,2013年9月至2022年6月在28国550个中心开展。
  • 纳入既往参加度普利尤单抗临床试验的成人中重度AD患者2677例,平均年龄39.2岁,男性1611例(60.2%)。
  • 给药方案初始为每周200mg(负荷400mg),后调整为每周300mg(负荷600mg),2019年11月改为每2周300mg。

主要发现

  • 334例(12.5%)完成至第260周治疗;退出原因包括监管批准后按方案退出(810/1380,58.7%)、患者退出(248/1380,18.0%)、不良事件(116/1380,8.4%)。
  • 治疗中出现的不良事件暴露调整率总体稳定或下降。
  • 常见不良事件(发生率≥5%)包括鼻咽炎、AD加重、上呼吸道感染、结膜炎、过敏性结膜炎、头痛、口腔疱疹、注射部位反应。
  • 第260周时,220/326例(67.5%)达到IGA 0或1,288/324例(88.9%)达到EASI 75%及以上改善。
  • EASI评分均值(SD)从基线16.39(14.60)降至研究结束时2.75(5.62)。

关键数值与推荐

  • 主要终点为治疗中出现的不良事件发生率和发生率。
  • 关键次要终点包括严重不良事件和特别关注不良事件的发生率、IGA 0/1比例、EASI 75%改善比例。

临床怎么用

  • 支持度普利尤单抗作为成人中重度AD的长期持续治疗方案。
  • 长期用药期间需关注常见不良事件如鼻咽炎、结膜炎和注射部位反应。

局限性

  • 开放标签扩展研究,无对照组。
  • 完成至第260周治疗的患者仅334例(12.5%),存在高脱落偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires continuous long-term systemic management. Long-term safety and efficacy data for treatment options are critically important. OBJECTIVE: To assess the safety and efficacy of dupilumab treatment for up to 5 years in adults with moderate to severe AD. DESIGN, SETTING, AND PARTICIPANTS: The 5-year LIBERTY AD open-label extension study was conducted from September 2013 to June 2022 at 550 sites in 28 countries. The study enrolled adult patients with moderate to severe AD who had participated in previous dupilumab clinical trials. Data were analyzed from August 2022 to February 2023. EXPOSURES: At enrollment, patients initiated a regimen of subcutaneous dupilumab, 200 mg, weekly (400-mg loading dose). The regimen was amended in June 2014 to dupilumab, 300 mg, weekly (600-mg loading dose) based on a dose-ranging study and again in November 2019 to dupilumab, 300 mg, every 2 weeks to align with the regulatory regimen approvals. MAIN OUTCOMES AND MEASURES: The primary end points were the incidence and rate of treatment-emergent adverse events (TEAEs). Key secondary end points included incidence and rate of serious TEAEs and adverse events of special interest, proportion of patients achieving an Investigator's Global Assessment (IGA) score of 0 or 1 (clear or almost clear), and proportion of patients with 75% or more improvement in the Eczema Area and Severity Index (EASI) from the parent study baseline. RESULTS: A total of 2677 patients were enrolled and treated in the open-label extension study; 1611 (60.2%) were male, and the mean (SD) age was 39.2 (13.4) years. A total of 334 patients (12.5%) completed treatment up to week 260. The most common reasons for withdrawal were due to regulatory approval of dupilumab in compliance with the study protocol (810 of 1380 [58.7%]), patient withdrawal (248 of 1380 [18.0%]), and adverse events (116 of 1380 [8.4%]). Exposure-adjusted rates of TEAEs were generally stable or declined throughout the study. Common TEAEs (incidence of 5% or greater) included nasopharyngitis, worsening AD, upper respiratory tract infection, conjunctivitis, conjunctivitis allergic, headache, oral herpes, and injection-site reaction. At week 260, 220 of 326 patients (67.5%) achieved an IGA score of 0 or 1 and 288 of 324 (88.9%) achieved 75% or greater improvement in the EASI. The mean (SD) EASI score was 16.39 (14.60) at baseline and 2.75 (5.62) at end of study. CONCLUSIONS AND RELEVANCE: In this study, there was sustained safety and efficacy of continuous long-term dupilumab treatment for adults with moderate to severe AD.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study. JAMA Dermatol. 2024. PMID: 38985486. doi:10.1001/jamadermatol.2024.1536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。